Analysts Set Aytu BioPharma Inc. (NASDAQ:AYTU) PT at $9.33

Shares of Aytu BioPharma Inc. (NASDAQ:AYTU) have been assigned an average rating of “Hold” from the five analysts that are covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $9.3333.

Several research analysts recently weighed in on AYTU shares. Wall Street Zen upgraded shares of Aytu BioPharma to a “hold” rating in a research report on Saturday, February 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Aytu BioPharma in a research report on Wednesday, April 8th. Finally, Zacks Research cut shares of Aytu BioPharma from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 31st.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of AYTU. Daytona Street Capital LLC bought a new position in shares of Aytu BioPharma in the fourth quarter worth approximately $26,000. Rothschild Wealth LLC bought a new position in shares of Aytu BioPharma in the fourth quarter worth approximately $52,000. Dimensional Fund Advisors LP bought a new position in shares of Aytu BioPharma in the third quarter worth approximately $58,000. Bellevue Asset Management LLC bought a new position in shares of Aytu BioPharma in the fourth quarter worth approximately $65,000. Finally, XTX Topco Ltd bought a new position in Aytu BioPharma during the fourth quarter valued at approximately $67,000. 33.49% of the stock is currently owned by institutional investors.

Aytu BioPharma Trading Down 0.4%

Shares of AYTU opened at $2.56 on Friday. The business’s 50-day moving average price is $2.59 and its 200-day moving average price is $2.44. Aytu BioPharma has a twelve month low of $1.20 and a twelve month high of $3.07. The stock has a market cap of $27.47 million, a PE ratio of -0.67 and a beta of 0.28. The company has a quick ratio of 1.03, a current ratio of 1.16 and a debt-to-equity ratio of 0.70.

Aytu BioPharma (NASDAQ:AYTU) last announced its quarterly earnings results on Tuesday, February 3rd. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.26) by ($0.79). Aytu BioPharma had a negative net margin of 39.02% and a negative return on equity of 28.22%. The company had revenue of $15.17 million for the quarter, compared to the consensus estimate of $12.17 million. On average, equities analysts forecast that Aytu BioPharma will post -0.69 EPS for the current fiscal year.

About Aytu BioPharma

Aytu BioPharma, Inc is a specialty pharmaceutical company focused on the development, licensing and commercialization of novel therapeutics to address underserved medical needs. Headquartered in Englewood, Colorado, Aytu pursues a strategy of acquiring late-stage or approved products in areas such as urology, endocrinology, women’s health, pediatric care and supportive therapies. The company leverages in-house commercialization capabilities and targeted business development to build a diversified portfolio of prescription medicines and diagnostics.

Aytu’s marketed portfolio includes Natesto, a nasal testosterone gel for treatment of male hypogonadism; ZolpiMist, a zolpidem tartrate lingual spray for the short-term treatment of insomnia; and Tuzistra XR, an extended-release cough syrup formulation indicated for relief of cough and upper respiratory symptoms.